Overview

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

Status:
RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.
Phase:
PHASE1
Details
Lead Sponsor:
Genentech, Inc.